I CLAIM:

1. A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient an effective dose of aerosolized cyclosporine directly following transplantation in an amount sufficient to prevent graft rejection.

2. The method of claim 1 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 15 and 30 mg in the lung.

3. The method of claim 1 wherein the cyclosporine is co-administered with a second immunosuppressive agent.

4. The method of claim 1 wherein the cyclosporine is co-administered with a anti-inflammatory reagent.

5. A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an amount of aerosolized cyclosporine effective to inhibit or ameliorate pulmonary inflammation.

6. The method of claim 5 wherein the pulmonary inflammation is associated with asthma, sarcoidosis, emphysema, cystic fibrosis, isiopathic pulmonary fibrosis, chronic bronchitis, or allergic rhinititis.

7. The method of claim 5 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 5 and 30 mg in the lung.

8. A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient an effective dose of aerosolized cyclosporine in an amount sufficient to prevent graft rejection.

9. The method of claim 8 wherein the dose of cyclosporine is sufficient to achieve circulating levels ranging between 50-250 ng/ml.

10. The method of claim 8 wherein the cyclosporine is co-administered with a second immunosuppressive agent.

11. A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising the administering to the subject an amount of cyclosporine effective to inhibit the immune response associated with the immune disorder.

12. A composition comprising a suitable carrier and aerosolized cyclosporine in doses sufficient to reduce pulmonary inflammation in subjects having pulmonary disorders.

13. The composition of claim 12 wherein the aerosolized cyclosporine has a particle size of between 1 and 5 microns.

14. The composition of Claim 12 wherein the dose is sufficient to achieve concentration levels of between 5-15 mg of cyclosporine in the lung.

15. The composition of Claim 12 wherein the carrier is propylene glycol.

16. A composition comprising aerosolized cyclosporine as a dry powder, having a particle size in the range between 1 and 5 microns.

17. A composition comprising a suitable carrier and aerosolized cyclosporine in doses sufficient to prevent development of an immune response that would lead to graft rejection in a transplant recipient.

18. The composition of claim 17 wherein the cyclosporine has a particle size of between .1 and 2 microns.